Ischemic Heart Disease Clinical Trial
— PM HeartOfficial title:
Clinical Implementation of a Novel Decision Support Tool in Patients With Ischemic Heart Disease
The PM-Heart algorithm (PMHeartIHD) is an in-house developed software that predict the survival prognosis for the individual patient hospitalized with ischemic heart disease (IHD) after a coronary arteriography has been performed. The software is intended to be used as a clinical decision support system i.e. the calculated survival prognosis is expected to enhance the quality of the treating physician's therapeutic considerations concerning (minor) adjustments to the patients treatment and follow-up - all within the framework of the current medical guidelines. Thus, the algorithm does not "show the physician specifically what to do", but rather ensures a better knowledgebase for the overall interpretation and choice of management of the patient.
Status | Recruiting |
Enrollment | 8000 |
Est. completion date | December 2026 |
Est. primary completion date | December 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Hospitalized patients in one of the involved departments of cardiology (see below) with; - Ischemic heart disease; the clinical presentation may be stable, worsening/unstable angina, non-ST-elevation myocardial infarction or ST-elevation myocardial infarction, and with - Significant coronary artery lesions or diffuse coronary artery disease on invasive coronary angiography during the admission Exclusion Criteria: - <18 years of age - Living outside Denmark |
Country | Name | City | State |
---|---|---|---|
Denmark | Department of Cardiology, The Heart Centre, Rigshospitalet Copenhagen University Hospital. | Copenhagen Ø |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark | Region Capital Denmark, Region Zealand |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number and duration of readmissions within one month after randomization | A composite outcome of a) readmissions within one month, and 2) all-cause mortality within one year - for patients randomized to the study.
All the outcomes listed below will be assessed as a comparison between the "intervention group" and the "control group". |
From randomization to the study and up to 1 year hereafter | |
Primary | Number and cause of death (all-cause mortality) within one year after randomization | A composite outcome of a) readmissions within one month, and 2) all-cause mortality within one year - for patients randomized to the study. | From randomization to the study and up to 1 year hereafter | |
Secondary | Readmission(s) within 30 days of the randomization | Readmission(s) within 30 days of the randomization. Incl. information on the quantity, duration, cause, outcome etc. | Up to 30 days after randomization to the study. | |
Secondary | Cardiovascular readmission(s) within 30 days of the randomization | Cardiovascular readmission(s) within 30 days of the randomization. Incl. information on the quantity, duration, cause, outcome etc. | Up to 30 days after randomization to the study. | |
Secondary | Readmission(s) with acute coronary syndrome | Readmission(s) with acute coronary syndrome. Incl. information on the quantity, duration, cause, outcome etc. | From randomization to the study and up to 1 year hereafter | |
Secondary | One-year survival | One-year survival | From randomization to the study and up to 1 year hereafter | |
Secondary | Total number of days the primary hospitalization lasts | Length (i.e. total number of days) of the primary hospitalization (i.e. when the patient is randomized to the study). | From randomization to the study and up to 1 year hereafter | |
Secondary | Total number of days at the hospital incl. hospitalizations during the first year after inclusion | Total number of days in hospital during the first year after inclusion | From randomization to the study and up to 1 year hereafter | |
Secondary | Number of hospitalizations the first year | Number of hospitalizations the first year | From randomization to the study and up to 1 year hereafter | |
Secondary | Number and type of performed cardiac investigations | Number and type of performed cardiac investigations; i.e. TTE, KAG, Heart-CT, Holter/R-tests, ECG, blood samples, etc. | From randomization to the study and up to 1 year hereafter | |
Secondary | Number of cardiac follow-up consultations at the hospital | Number of cardiac follow-up consultations at the hospital | From randomization to the study and up to 1 year hereafter | |
Secondary | Number of check-ups for cardiovascular reasons at the general practitioner | Number of check-ups for cardiovascular reasons at the general practitioner. | From randomization to the study and up to 1 year hereafter | |
Secondary | Number of cardiovascular drugs at discharge | Number of cardiovascular drugs at discharge + after 1 year. | From randomization to the study and up to 1 year hereafter | |
Secondary | Dosages (DDD) of drugs at discharge | Dosages (DDD) of drugs at discharge + after 1 year. | Up to 1 year after randomization to study. | |
Secondary | Incidence of a) new ischemic events, b) arrhythmias, c) and/or heart failure | Incidence of a) new ischemic events, b) arrhythmias, c) and/or heart failure | Up to 1 year after randomization to study. | |
Secondary | Health economic analyses of implementing the algorithm | Health economic analyses: How does implementing the algorithm alter the overall costs and resource spending, incl. e.g. social benefits, compared with standard-of-care.
i.e. does knowing a more precise 1-year mortality prediction reduce/increase the resource consumption. Will be based on economic analyses of the costs related to the abovementioned outcome measurements. |
Up to 1 year after randomization to study. | |
Secondary | The algorithm's reception and introduction in clinical use | We wish to investigate how the algorithm is introduced and received in the clinic, both by the medical staff but also the patients.
Will be investigated using interviews. |
Before start of clinical study and up to 1 year after randomization to study. | |
Secondary | The usability of the algorithm | The usability of the algorithm i.e. is it easy to use/understand, any praise or criticisms, ideas for new features etc.
Will be based on questionaires and feedback from users. |
Before start of clinical study and up to 1 year after randomization to study. | |
Secondary | How, and to what extend, is the algorithm used by the medical staff. | We wish to investigate how, and to what extend, the algorithm is used by the medical staff, e.g. are the medical staff inclined to use the prediction, does it alter their treatment choices etc.
Will be based on questionaires, interviews, feedback from users, and assessment of "look-ups". |
Before start of clinical study and up to 1 year after randomization to study. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Active, not recruiting |
NCT04562805 -
Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)
|
N/A | |
Recruiting |
NCT05292079 -
CAPTURER PMCF Study ( rEPIC04D )
|
||
Recruiting |
NCT05292014 -
ANGIOLITE PMCF Study ( rEPIC04F )
|
||
Recruiting |
NCT05292092 -
Essential Pro PMCF Study ( rEPIC04E )
|
||
Recruiting |
NCT05292118 -
Navitian PMCF Study ( rEPIC04C )
|
||
Completed |
NCT05292105 -
NC Xperience PMCF Study( rEPIC04B)
|
||
Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
Not yet recruiting |
NCT04153383 -
Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
|
||
Recruiting |
NCT02729064 -
Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose
|
Phase 1 | |
Recruiting |
NCT02982434 -
The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
|
Phase 2 | |
Completed |
NCT02468401 -
Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions
|
N/A | |
Completed |
NCT02759406 -
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
|
N/A | |
Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
Completed |
NCT01604213 -
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01699802 -
Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)
|
N/A | |
Completed |
NCT01724567 -
Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training
|
N/A | |
Completed |
NCT01334268 -
RESOLUTE China RCT
|
N/A | |
Completed |
NCT02159235 -
Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)
|
N/A |